<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882373</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1105</org_study_id>
    <secondary_id>NCI-2018-02537</secondary_id>
    <secondary_id>2015-1105</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02882373</nct_id>
  </id_info>
  <brief_title>Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury</brief_title>
  <official_title>L-Arginine For Anti-VEGF Induced Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well arginine works in treating patients with kidney injury
      caused by anti-VEGF drugs used in standard treatment for cancer. Arginine is a nutritional
      supplement that may control side effects of anti-cancer drugs such as high blood pressure and
      protein in the urine and may also help to improve kidney function in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the value and/or limitations of using orally supplemented arginine (L-arginine)
      to improve renal function associated with the use of anti-angiogenic therapies that target
      vascular endothelial growth factor (VEGF).

      OUTLINE: Patients are randomized to 1 of 2 groups.

      GROUP I: Patients receive arginine orally (PO) four times daily (QID). Treatment continues
      for up to 3 months in the absence of disease progression or unacceptable toxicity.

      GROUP II: Patience receive placebo PO QID. Treatment continues for up to 3 months in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment patients are followed up within 1 month.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Principal Investigator's Request
  </why_stopped>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in proteinuria as measured by protein-creatinine ratio (UPC) &gt; 500 mg/day</measure>
    <time_frame>Baseline up to 3 months</time_frame>
    <description>Linear mixed effects regression will be utilized to analyze the longitudinal change of UPC between treatment and placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved glomerular filtration rate (GFR) &gt;= 25%</measure>
    <time_frame>Baseline up to 3 months</time_frame>
    <description>Linear mixed effects regression will be utilized to analyze the GFR between treatment and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in systolic blood pressure (SBP) &gt;= 10 mmHg and/or diastolic blood pressure &gt;= 5 mmHg</measure>
    <time_frame>Baseline up to 3 months</time_frame>
    <description>Linear mixed effects regression will be utilized to analyze the SBP between treatment and placebo groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Drug-Induced Nephropathy</condition>
  <condition>Hypertension</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Group I (arginine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive arginine PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patience receive placebo PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arginine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (arginine)</arm_group_label>
    <other_name>Amino-5-guanidino-pentanoic acid</other_name>
    <other_name>Arg</other_name>
    <other_name>L-Arginine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group II (placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On or enrolled for anti-VEGF therapy

          -  Systolic Blood Pressure &gt;= 140 mm Hg

          -  Diastolic Blood Pressure &gt;= 90 mm Hg

          -  Proteinuria &gt;= 500 mg/day or worsening glomerular filtration rate (GFR) (&gt; 0.3 mg/dl
             in 48 hours [hrs.] or &gt; 50% decline from baseline creatinine in 1 week)

        Exclusion Criteria:

          -  Allergy to L-arginine

          -  Systolic Blood Pressure &lt; 140 mm Hg

          -  Diastolic Blood Pressure &lt; 90 mm Hg

          -  Proteinuria &lt; 500 mg/day

          -  Continuous tube feeds (since the medication will be given in-between meals)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Danesh</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2016</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

